Marks Group Wealth Management Inc Acquires 4,647 Shares of Icon Plc $ICLR

Marks Group Wealth Management Inc increased its holdings in shares of Icon Plc (NASDAQ:ICLR) by 10.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 50,201 shares of the medical research company’s stock after acquiring an additional 4,647 shares during the quarter. Marks Group Wealth Management Inc owned about 0.06% of Icon worth $5,555,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Toth Financial Advisory Corp bought a new position in shares of Icon in the fourth quarter valued at about $27,000. EFG International AG bought a new position in Icon in the 4th quarter valued at about $27,000. Abound Financial LLC acquired a new stake in Icon during the fourth quarter worth approximately $54,000. Johnson Financial Group Inc. bought a new stake in shares of Icon during the third quarter worth approximately $71,000. Finally, Quadrant Capital Group LLC acquired a new position in shares of Icon in the third quarter valued at approximately $78,000. 95.61% of the stock is owned by institutional investors.

Icon Stock Performance

NASDAQ:ICLR opened at $172.08 on Thursday. Icon Plc has a twelve month low of $66.57 and a twelve month high of $211.00. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 0.31. The stock’s 50-day simple moving average is $144.41 and its 200 day simple moving average is $136.87. The firm has a market capitalization of $13.18 billion, a PE ratio of 30.62, a price-to-earnings-growth ratio of 8.24 and a beta of 1.22.

Icon (NASDAQ:ICLR) last posted its earnings results on Tuesday, June 23rd. The medical research company reported $2.50 EPS for the quarter, topping analysts’ consensus estimates of $2.43 by $0.07. Icon had a net margin of 5.35% and a return on equity of 8.73%. The firm had revenue of $2.03 billion during the quarter, compared to analysts’ expectations of $1.98 billion. During the same quarter in the prior year, the business earned $3.43 earnings per share. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. On average, analysts anticipate that Icon Plc will post 9.43 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Robert W. Baird boosted their price target on Icon from $168.00 to $186.00 and gave the company an “outperform” rating in a research note on Thursday, June 25th. Truist Financial raised shares of Icon from a “hold” rating to a “buy” rating and boosted their target price for the company from $159.00 to $207.00 in a research report on Tuesday, June 30th. Bank of America raised their price target on shares of Icon from $125.00 to $150.00 and gave the stock an “underperform” rating in a research report on Thursday, June 25th. JPMorgan Chase & Co. boosted their price objective on shares of Icon from $130.00 to $155.00 and gave the company a “neutral” rating in a report on Thursday, June 25th. Finally, Weiss Ratings cut shares of Icon from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, May 29th. Nine investment analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, Icon has a consensus rating of “Hold” and an average target price of $173.19.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.